PHASE I TRIAL OF HuM291, A HUMANIZED ANTI-CD3 ANTIBODY, IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM LIVING DONORS1

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Transplantation

• Publication date

  2000-12-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00007890-200012270-00008PMID 11152101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Muromonab CD3

  2012cited by this paper
• Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.

  1999cited by this paper
• A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees.

  1999cited by this paper
• HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.

  1999cited by this paper
• Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients.

  1998cited by this paper
• Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.

  1996cited by this paper
• Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.

  1996cited by this paper
• Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.

  1996cited by this paper
• Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review.

  1995cited by this paper
• The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation.

  1995cited by this paper
• General aspects of cytokine-release syndrome: timing and incidence of symptoms.

  1993cited by this paper
• PREDICTION OF SUCCESSFUL ALLOGRAFT REJECTION RETREATMENT WITH OKT31,2

  1992cited by this paper
• Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.

  1992cited by this paper
• OKT3 first-dose reaction: association with T cell subsets and cytokine release.

  1991cited by this paper
• Activation of human T cells in vivo following treatment of transplant recipients with OKT3.

  1990cited by this paper
• IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION: SYSTEMIC CYTOKINE RELEASE AND MODULATION BY CORTICOSTEROIDS

  1990cited by this paper
• The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells.

  1990influential reference
• Neurotoxicity after treatment with muromonab-CD3.

  1990cited by this paper
• RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN‐2, AND GAMMA‐INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTS

  1989cited by this paper
• Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation.

  1989cited by this paper
• Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected].

  1989cited by this paper
• Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection.

  1988cited by this paper
• Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection.

  1988cited by this paper
• The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy.

  1988cited by this paper
• Effects of HLA matching in cadaver renal transplants.

  1988cited by this paper
• Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody.

  1987cited by this paper
• A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection.

  1987cited by this paper
• A RANDOMIZED CLINICAL TRIAL COMPARING OKT3 AND STEROIDS FOR TREATMENT OF HEPATIC ALLOGRAFT REJECTION

  1987cited by this paper
• Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppressive regimens.

  1987cited by this paper
• A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.

  1985cited by this paper
• EVOLVING USE OF OKT3 MONOCLONAL ANTIBODY FOR TREATMENT OF RENAL ALLOGRAFT REJECTION

  1984cited by this paper
• Human in vivo antigenic modulation induced by the anti‐T cell OKT3 monoclonal antibody

  1982influential reference
• In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia.

  1981cited by this paper
• Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.

  1981cited by this paper

• Antibody‐Conjugated Magnetic Nanoparticle Therapy for Inhibiting T‐Cell Mediated Inflammation

  2023cites this paper
• Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins

  2020cites this paper
• Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format

  2019cites this paper
• Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

  2018influential citation
• Immune rebalancing by oral immunotherapy: A novel method for getting the immune system back on track

  2018cites this paper
• Significance of biologics in renal transplantation: past, present, and future

  2017cites this paper
• Safety Considerations for Biologics

  2017cites this paper
• 7. Fc Engineering

  2014cites this paper
• Characterization of a surrogate murine antibody to model anti-human CD3 therapies

  2013cites this paper
• Nonclinical Safety Assessment: Biotechnology‐Derived Pharmaceuticals

  2013cites this paper
• Immunosuppressive drug therapy.

  2013cites this paper
• Immunotherapy for De Novo Renal Transplantation

  2012cites this paper
• Long term amelioration of established collagen-induced arthritis achieved with short term therapy combining anti-CD3 and anti-TNF treatments

  2012cites this paper
• Otelixizumab in the treatment of type 1 diabetes mellitus.

  2011cites this paper
• The novel non-mitogenic anti-CD3 antibody, mini-yCD3, delivers a partial TCR signal.

  2010cites this paper
• Induction therapy: Why, when, and which agent?

  2010cites this paper
• Antibody immunosuppressive therapy in solid-organ transplant

  2010cites this paper
• Antibody immunosuppressive therapy in solid organ transplant

  2010cites this paper
• Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome.

  2010cites this paper
• Prospective randomized open‐label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid‐refractory ulcerative colitis†

  2010cites this paper
• Immunotoxicology of Biopharmaceutics

  2010cites this paper
• Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis

  2010cites this paper
• General Toxicity Testing and Immunotoxicity Testing for Biopharmaceuticals

  2010cites this paper
• Antibody immunosuppressive therapy in solid-organ transplant: Part I.

  2010cites this paper
• Construction of a Recombinant Non-Mitogenic Anti-Human CD3 Antibody

  2010cites this paper
• Radiolabeled Humanized Anti-CD3 Monoclonal Antibody Visilizumab for Imaging Human T-Lymphocytes

  2009cites this paper
• Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies

  2009influential citation
• Monoclonal antibody therapy

  2009cites this paper
• Transient Cytokine-Induced Liver Injury Following Administration of the Humanized Anti-CD3 Antibody Visilizumab (HuM291) in Crohn's Disease

  2009cites this paper
• New directions for induction immunosuppression strategy in solid organ transplantation.

  2009cites this paper
• The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?

  2009influential citation
• Monoclonal antibody-induced cytokine-release syndrome

  2009cites this paper
• Evolving trends in induction therapy.

  2009cites this paper
• [New therapeutic targets for antibodies and recombinant proteins in organ transplantation].

  2008cites this paper
• Nouvelles biothérapies immunosuppressives dans les transplantations d’organes

  2008cites this paper
• Relevant Immune Tests across Different Species and Surrogate Models

  2008cites this paper
• Considerations for the development of therapeutic monoclonal antibodies.

  2008cites this paper
• Differentiation between Desired Immunomodulation and Potential Immunotoxicity

  2008cites this paper
• Anti-CD3: from T cell depletion to tolerance induction

  2008cites this paper
• Chapter 20 – Antibodies and Fusion Proteins

  2008cites this paper
• Preclinical and clinical safety of monoclonal antibodies.

  2007cites this paper
• Structured to reduce the mitogenicity of anti-CD3 antibody based on computer-guided molecular design.

  2007cites this paper
• New therapeutic targets for antibodies and recombinant proteins in organ transplantation.

  2007cites this paper
• Monitorización y efectos secundarios de los inmunosupresores en el transplante

  2007cites this paper
• Immunotherapy for De Novo renal transplantation: what's in the pipeline?

  2006cites this paper
• Induction Immunosuppression

  2006cites this paper
• Potent antibody therapeutics by design

  2006cites this paper
• Le traitement immunosuppresseur en transplantation rénale pédiatrique Immunosuppressive agents in pediatric renal transplantation

  2005cites this paper
• 86 – New Approaches in Immunosuppression

  2005cites this paper
• Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.

  2005cites this paper
• Monoclonal antibodies and fusion proteins in medicine.

  2005cites this paper
• T cell targeted immunotherapy for autoimmune disease

  2005cites this paper
• Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.

  2004cites this paper
• drug therapy Immunosuppressive Drugs for Kidney Transplantation

  2004cites this paper
• Current and Future Immunosuppressive Strategies in Renal Transplantation

  2004cites this paper
• Immunosuppressive drugs for kidney transplantation.

  2004cites this paper
• Clinical Trials of Transplant Tolerance: Slow But Steady Progress

  2003cites this paper
• Immunosuppressive Agents on the Horizon

  2003cites this paper
• Novel therapies in the treatment of ulcerative colitis

  2003cites this paper
• Engineered CD3 antibodies for immunosuppression

  2003cites this paper
• Treatment of acute kidney allograft rejection with a non‐mitogenic CD3 antibody

  2003cites this paper
• What's in the Pipeline? New Immunosuppressive Drugs in Transplantation

  2002cites this paper
• Novel therapies in the treatment of ulcerative colitis

  2001cites this paper
• Renal Transplantation Update Series Editor: V. Ram Peddi and M. Roy First: Recent Advances in Immunosuppressive Therapy for Renal Transplantation

  2001cites this paper
• Immunosuppressive strategies for prevention of transplant rejection

  2001cites this paper
• Neurotoxicity of immunosuppressive drugs

  2001cites this paper